This study will formulate and perform preclinical studies of an anti-inflammatory microbiota metabolite for in vivo evaluation.
Formulated gels will be assessed for their physicochemical properties, ability to dampen inflammation in cervicovaginal epithelial cells in vitro, kill non-optimal vaginal bacteria, and their safety in a three-dimensional vaginal tissue model,
A non-optimal vaginal microbiome increases the risk of a women acquiring HIV by >4-fold and transmitting HIV to their male partners. Developing a vaginal gel that dampens genital inflammation could be used by women to decrease HIV transmission.
Funding
Partners
- NHMRC
- ACH2
- Campbell Foundation
- MRFF
Partners +
Collaborators
- Dr Anna Hearps
- Dr LIndi Masson
- Professor Catriona Bradshaw
- Professor Jacques Ravel
- Dr Simon Moulton
- Dr Simon Cook
- Dr Seyoum Ayenhunie
- Dr Lenka Vodstrcil
- Professor Deborah Bateson
- Dr Erica Plummer
Project
Team
Meet the project team. Together, we are translating research into better health, for all.
Publications
VIEW ALL RESEARCHTyssen D, Hearps AC, Guntur K, Masson L, Cook S, Moulton SE, Ravel J, Bradshaw CS, Ayehunie S, Tachedjian G
- Frontiers in reproductive health
- 23 Jun 2022